Related Experiment Video
Updated: May 7, 2026
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines
Hai-Hong Zhang1, Zhi-Yi Zhang, Chun-Li Che
1Department of rheumatism and immunology, First Clinical Medical College affiliated to Harbin Medical University Harbin, China.
Abstract:
Gemcitabine is one of the most widely used drugs for the treatment of advanced Non-small cell lung cancer (NSCLC), but modest objective response rate of patients to gemcitabine makes it necessary to identify novel biomarkers for patients who can benefit from gemcitabine-based therapy and to improve the effect of clinical therapy. In this work, 3 NSCLC cell lines displaying different sensitivities to gemcitabine were applied for mRNA and microRNA (miR) expression chips to figure out the biomarkers for gemcitabine sensitivity. Genes whose expression increased dramatically in sensitive cell lines were mainly enriched in cell adhesion (NRP2, CXCR3, CDK5R1, IL32 and CDH2) and secretory granule (SLC11A1, GP5, CD36 and IGF1), while genes with significantly upregulated expression in resistant cell line were mainly clustered in methylation modification (HIST1H2BF, RAB23 and TP53) and oxidoreductase (TP53I3, CYP27B1 and SOD3). The most intriguing is the activation of Wnt/β-catenin signaling in gemcitabine resistant NSCLC cell lines. The miR-155, miR-10a, miR-30a, miR-24-2* and miR-30c-2* were upregulated in sensitive cell lines, while expression of miR-200c, miR-203, miR-885-5p, miR-195 and miR-25* was increased in resistant cell line. Genes with significantly altered expression and putatively mediated by the expression-changed miRs were mainly enriched in chromatin assembly (MAF, HLF, BCL2, and IGSF3), anti-apoptosis (BCL2, IGF1 and IKBKB), protein kinase (NRP2, PAK7 and CDK5R1) (all the above genes were upregulated in sensitive cells) and small GTPase mediated signal transduction (GNA13, RAP2A, ARHGAP5 and RAB23, down-regulated in sensitive cells). Our results might provide potential biomarkers for gemcitabine sensitivity prediction and putative targets to overcome gemcitabine resistance in NSCLC patients.
Insights
Researchers identified gene and microRNA biomarkers to predict gemcitabine sensitivity in non-small cell lung cancer (NSCLC). This could improve treatment selection and overcome gemcitabine resistance in NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Gemcitabine is a key treatment for advanced non-small cell lung cancer (NSCLC).
- Limited response rates necessitate biomarkers for personalized therapy and improved outcomes.
- Understanding gemcitabine sensitivity mechanisms is crucial for effective NSCLC treatment.
Purpose of the Study:
- To identify novel mRNA and microRNA (miR) biomarkers associated with gemcitabine sensitivity in NSCLC.
- To explore molecular pathways involved in gemcitabine resistance and sensitivity.
- To provide potential targets for overcoming gemcitabine resistance in NSCLC patients.
Main Methods:
- Utilized mRNA and microRNA expression profiling on three NSCLC cell lines with varying gemcitabine sensitivities.
- Analyzed gene expression patterns, focusing on upregulated genes in sensitive and resistant cell lines.
- Investigated microRNA expression changes and their potential mediation of gene expression alterations.
Main Results:
- Sensitive NSCLC cells showed enrichment in cell adhesion and secretory granule pathways.
- Resistant NSCLC cells exhibited upregulation in methylation modification and oxidoreductase pathways, with activated Wnt/β-catenin signaling.
- Distinct microRNA profiles were observed in sensitive (e.g., miR-155) and resistant (e.g., miR-200c) cell lines, correlating with altered gene expression in pathways like chromatin assembly and anti-apoptosis.
Conclusions:
- Identified specific genes and microRNAs as potential biomarkers for predicting gemcitabine sensitivity in NSCLC.
- Elucidated molecular mechanisms, including Wnt/β-catenin signaling and microRNA-mediated gene regulation, contributing to gemcitabine resistance.
- Findings offer potential therapeutic targets to enhance gemcitabine efficacy and overcome resistance in NSCLC treatment.
